LP(A) AND CARDIOVASCULAR OUTCOMES: AN ANALYSIS FROM THE ODYSSEY OUTCOMES TRIAL

被引：15

作者：

Bittner, Vera ^{[1
]}

Szarek, Michael ^{[2
]}

Aylward, Philip E. ^{[3
]}

Bhatt, Deepak L. ^{[4
,5
]}

Diaz, Rafael ^{[6
]}

Fras, Zlatko ^{[7
]}

Goodman, Shaun ^{[8
]}

Hanotin, Corinne ^{[10
]}

Harrington, Robert ^{[9
]}

Jukema, J. W. ^{[11
]}

Loizeau, Virginie ^{[10
]}

Moriarty, Patrick ^{[12
]}

Moryusef, Angele ^{[13
]}

Pordy, Robert ^{[14
]}

Roe, Matthew T. ^{[15
]}

Sinnaeve, Peter ^{[16
]}

White, Harvey D. ^{[17
]}

Zahger, Doron ^{[18
]}

Zeiher, Andreas ^{[19
]}

Steg, Ph G. ^{[20
]}

Schwartz, Gregory ^{[21
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Suny Downstate Med Ctr, New York, NY USA

[3] Flinders Univ & Med Ctr, South Australian Hlth & Med Res Inst, Adelaide, SA 5001, Australia

[4] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA USA

[6] Estudios Cardiol Latinoamer, Rosario, Santa Fe, Argentina

[7] Univ Ljubljana, Ljubljana, Slovenia

[8] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[9] Stanford Univ, Stanford, CA 94305 USA

[10] Sanofi, Paris, France

[11] Leiden Univ, Med Ctr, Leiden, Netherlands

[12] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[13] Sanofi, Bridgewater, NJ USA

[14] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[15] Duke Univ, Duke Clin Res Inst, Durham, NC USA

[16] UZ Leuven, Leuven, Belgium

[17] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand

[18] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Beer Sheva, Israel

[19] Goethe Univ, Frankfurt, Germany

[20] Hop Bicetre, AP HP, Paris, France

[21] Univ Colorado, Aurora, CO USA

来源：

ATHEROSCLEROSIS SUPPLEMENTS | 2018年 / 32卷

关键词：

D O I：

10.1016/j.atherosclerosissup.2018.04.072

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

C3-5.01

引用

页码：24 / 25

页数：2

共 50 条

[41] Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Schwartz, Gregory G.
Bessac, Laurence
Berdan, Lisa G.
Bhatt, Deepak L.
Bittner, Vera
Diaz, Rafael
Goodman, Shaun G.
Hanotin, Corinne
Harrington, Robert A.
Jukema, J. Wouter
Mahaffey, Kenneth W.
Moryusef, Angele
Pordy, Robert
Roe, Matthew T.
Rorick, Tyrus
Sasiela, William J.
Shirodaria, Cheerag
Szarek, Michael
Tamby, Jean-Francois
Tricoci, Pierluigi
White, Harvey
Zeiher, Andreas
Steg, Philippe Gabriel
AMERICAN HEART JOURNAL, 2014, 168 (05) : 682 - 689
[42] Gender differences in cardiovascular risk, treatment, and outcomes: a post-hoc analysis from the REWIND trial
Ferrannini, G.
Maldonado, J. M.
Raha, S.
Rao-Melacini, P.
Khatun, R.
Atisso, C.
Shurzinske, L.
Gerstein, H.
Ryden, L.
Bethel, M. A.
DIABETOLOGIA, 2021, 64 (SUPPL 1) : 4 - 5
[43] APOLIPOPROTEIN B, PCSK9 INHIBITION WITH ALIROCUMAB, AND ISCHEMIC CARDIOVASCULAR EVENTS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL
Hagstrom, Emil
Steg, Philippe Gabriel
Szarek, Michael
Bhatt, Deepak
Bittner, Vera
Danchin, Nicolas
Diaz, Rafael
Goodman, Shaun
Harrington, Robert A.
Jukema, Johan Wouter
Kim, Yong-Un
Liberopoulos, Evangelos
Marx, Nikolaus
McGinniss, Jennifer
Roe, Matthew
Louie, Michael
White, Harvey
Zeiher, Andreas
Schwartz, Gregory G.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 75 - 75
[44] Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial
Murphy, William A.
Lin, Nan
Damask, Amy
Schwartz, Gregory G.
Steg, P. Gabriel
Szarek, Michael
Banerjee, Poulabi
Fazio, Sergio
Manvelian, Garen
Pordy, Robert
Shuldiner, Alan R.
Paulding, Charles
CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2022, 15 (03): : E003503
[45] Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
Ostadal, Petr
Steg, Philippe Gabriel
Poulouin, Yann
Bhatt, Deepak L.
Bittner, Vera A.
Chua, Terrence
Diaz, Rafael
Goodman, Shaun G.
Huo, Yong
Jukema, Johan Wouter
Karpov, Yuri
Pordy, Robert
Scemama, Michel
Szarek, Michael
White, Harvey D.
Schwartz, Gregory G.
LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (05): : 330 - 340
[46] Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
Koomen, Jeroen, V
Heerspink, Hiddo J. L.
Schrieks, Ilse C.
Schwartz, Gregory G.
Lincoff, Michael
Nicholls, Stephen J.
Svensson, Anders
Wedel, Hans
Weichert, Arlette
Grobbee, Diederick E.
Stevens, Jasper
DIABETES OBESITY & METABOLISM, 2020, 22 (01): : 30 - 38
[47] Semaglutide and cardiovascular outcomes by blood pressure in the SELECT trial
Verma, Subodh
Deanfield, John
Arbel, Yaron
Cariou, Bertrand
Matos, Ana Laura S. A.
Hovingh, G. Kees
Jeppesen, Ole Kleist
Kahn, Steven
Latkovskis, Gustavs
Lingvay, Ildiko
Maeng, Michael
Maher, Vincent
Parkhomenko, Oleksandr
Poulter, Neil
van de Borne, Philippe
Kure, Peter
Lincoff, Abraham
CIRCULATION, 2024, 150
[48] Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial
Lee, Matthew M. Y.
Kristensen, Soren L.
Gerstein, Hertzel C.
McMurray, John J., V
Sattar, Naveed
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2022, 16 (01)
[49] Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta-analysis studies
Foos, V.
Lloyd, A.
Freemantle, N.
Grant, D.
Herman, W.
DIABETOLOGIA, 2011, 54 : S8 - S8
[50] Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
Oshima, Megumi
Neuen, Brendon L.
Li, JingWei
Perkovic, Vlado
Charytan, David M.
de Zeeuw, Dick
Edwards, Robert
Greene, Tom
Levin, Adeera
Mahaffey, Kenneth W.
De Nicola, Luca
Pollock, Carol
Rosenthal, Norman
Wheeler, David C.
Jardine, Meg J.
Heerspink, Hiddo J. L.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 31 (12): : 2925 - 2936

← 1 2 3 4 5 →